# RECEIVED

JUN 2 8 2002



Approved for use Text Approved for use Text

Substitute for form 1449/07 TO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 2

TAIG OND CONTON NEWFOOT.
10/075,673
February 13, 2002
J. Guy Breitenbucher et
al.
1619
ORT-1590

				U.S. PATENT DOCUMENTS		
Examiner Initials	Cite	U.S. Patent Do	Kind Code <sup>2</sup>	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant passages or relevant figures appear
initials	No.1	Number	(if known)		mm-dd-yyyy	or relevant ligures appear
54		4,500,525		Winters , et al.	02-19-1985	
		5,264,576		Shutske, et al.	11-23-1993	
		5,776,718		Palmer, et al.	07-07-1998	
		5,976,858		Palmer, et al.	11-02-1999	
5v		6,030,946		Klaus, et al.	02-29-2000	
,						
					·	•
		· · · · · · · · · · · · · · · · · · ·				

FOREIGN PATENT DOCUMENTS

		Foreign Patent Document			Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant	
Examiner Initials	Cite No. <sup>1</sup>	Office <sup>3</sup>	Number⁴ Ki	indCode <sup>5</sup>	Applicant of Cited Document	mm-dd-yyyy	passages or relevant figures appear	T <sup>®</sup>
30	1	EP	382637	B1	Laboratorios del Dr. Esteve, S.A.	07-28-1993		
		EP	502786	B1	Laboratorios del Dr. Esteve, S.A.	04-24-1996		
		EP	655248	B1	Laboratorios del Dr. Esteve, S.A.	09-15-1999		
		wo	97/21439	A1	Laboratorios del Dr. Esteve, S.A.	06-19-1997		
41	1	wo	99/24460	A2	Novartis AG	05-20-1999		

	 The second secon	 			
Examiner		Date	11/10	107	
Signature	-0	Considered	11110	70)	
	 	 11050.00	11 11 1 11 11 11	1	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not no conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark

Onice, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



<sup>1</sup> Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

## RECEIVED

JUN 2 6 2002

JUN 2 5 2002 State Page Angrik Reduction Act at 1955.

Approved for the Approv

Substitute for form 1449A/P CRADEMARY

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 2

a collection of information unless it displays a	a valid OMB control number.
Application Number	10/075,673
Filing Date	February 13, 2002
First Named Inventor	J. Guy Breitenbucher et al.
Group Art Unit	1619
Examiner Name	
Attorney Docket Number	ORT-1590

				U.S. PATENT DOCUMENTS			
		U.S. Patent Do	cument		Date of Publication	Pages, Columns, Lines,	
Examiner Initials	Cite No.1	sitiala	Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	of Cited Document mm-dd-yyyy	where relevant passages or relevant figures appear
		6,287,840	B1	Palmer, J. T. et al.	09-11-2001		
						·	
·							
		<del> </del>					
	İ,				İ	,.	

#### **FOREIGN PATENT DOCUMENTS** Foreign Patent Document Date of Publication Pages, Columns, Lines, of Cited Document where relevant Name of Patentee or passages or relevant Examiner Cite mm-dd-yyyy T<sup>6</sup> Applicant of Cited Document figures appear Initials Number⁴ KindCode5 Office<sup>3</sup> No.1 WO 95/23222 A1 Khepri Pharmaceuticals, Inc. 08-31-1995 wo 96/30353 **A1** Arris Pharmaceutical Corporation 10-03-1996 wo 97/40066 Α1 Mass. Institute of Technology -10-30-1997 Brigham & Women's Hospital WO 99/58153 Α1 Brigham & Women's Hospital 11-18-1999

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.



## RECEIVED

JUN 2 6 2002
PTO/Seroax (68-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Officer U.S. PERABTHENT OF COMMERCE to a collection of information unlask fill distributes and 10 MR collection of information unlask fill distributes and 10 MR collection of information unlask fill distributes.

### INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 2

a collection of information unlest didiplats.	
Application Number	10/075,673
Filing Date	February 13, 2002
First Named Inventor	J. Guy Breitenbucher et
	al.
Group Art Unit	1619
Examiner Name	
Attorney Docket Number	ORT-1590

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
		Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item	T <sup>2</sup>
Examiner's	Cite	(book, magazine, journal, senal, symposium, catalog, etc.), date, page(s), volume-issue number(s),	1
Initials*	No.1	publisher, city and/or country where published	
		ALLEN, E.M. et al, "Reversible Cathepsin S (CATS) Inhibitors Block Invariant Chain Degradation Both In Vitro and In Vivo"	
		Inflammation Research (2001) Sup 3, Vol. 50, p S159 abstr. 10/04  BROMME, D. et al.: "Peptidyl vinyl sulphones: a new class of potent and selective cysteine protease inhibitors"; Biochem. J.	<del></del>
		(1996) 315:85-89	
-		CHAPMAN, H.A. et al.; "Emerging Roles For Cysteine Proteases in Human Biology"; Annu. Rev. Physiol. (1997) 59:63-88	
		CHAPMAN, H.A. "Endosomal Proteolysis and MHC Class II Function"; Curr. Opin. Immunol. (1998) 10:93-102	
		HONEY, K. et al.; "Role of Lysosomal Cysteine Proteinases in Antigen Presentation to CD4 T Cells"; Inflammation Research (2001) Sup.3, Vol. 50, pS159 abstr. 10/01	
		LI, W. et al.; ""Tissue Specific Expression of Cathepsins and Antigen Presentation"; Inflammation Research (2001) Sup 3, Vol. 50 p S159 abstr. 10/02	
		MAGILL, C. et al.; "Cysteine Proteases in Antigen Presentation and Models of Inflammation"; Inflammation Research (2001) Sup 3, Vol 50, p S159, abstr. 10/03	
		MAURER, D. et al., "Fce Receptor I on Dendritic Cells Delivers IgE-Bound Multivalent Antigens into a Cathepsin S- Dependent Pathway of MHC Class II Presentation" J. Immunol. (1998) 161:2731-2739	
		MCGRATH, M.E. et al.: "Crystal structure of human cathepsin S"; Protein Science (1998) 7:1294-1302	
		NAKAGAWA, T. Y. et al.; "Impaired Invariant Chain Degradation and Antigen Presentation and Diminished Collagen-Induced Arthritis in Cathepsin S Null Mice"; Immunity (1999) 10:207-217	
		NAKAGAWA, T.Y. et al.: "The role of lysosomal proteinases in MHC class II-mediated antigen processing and presentation" Immunological Rev. (1999) 172:121-129	
		NERENBERG, J. B. et al.; "Design and Synthesis of N-Alkylated Saccharins as Selective a-1A Adrenergic Receptor Antagonists"; Bioorg. Med. Chem. Lett. (1998) 8:2467-2472	
		PALMER, J. T. et al.; "Vinyl Sulfones as Mechanism-Based Cysteine Protease Inhibitors"; J. Med. Chem. (1995) 38(17):3193-3196	
		PODOLIN, P.L. et al.; "Inhibition of Cathepsin S Blocks Invariant Chain Processing and Antigen-Induced Proliferation In Vitro and Reduces the Severity of Collagen-Induced, Arthritis In Vivo"; Inflammation Research (2001) Sup 3, Vol. 50, p S 159 abstr. 10/05	
		RIESE, R. J. et al.; "Cathepsin S Activity Regulates Antigen Presentation and Immunity"; J. Clin Invest. (1998) 101 (11):2351-2363	
		RIESE, R.J. et al.; "Cathepsins and Compartmentalization in Antigen Presentation"; Curr. Opin. Immunol. (2000) 12:107-113	
		SHI, Guo-Ping, et al.; "Cathepsin S Required for Normal MHC Class II Peptide Loading and Germinal Center Development"; Immunity (1999) 10:197-206	
		SPERO, D. et al.; "Design and Synthesis of Novel Cathepsin S Inhibitors"; Inflammation Research (2001) Sup. 3, Vol. 50, p S206, abstr. 079	
		VILLADANGOS, J. A. et al.; "Degradation of Mouse Invariant Chain: Roles of Cathepsins S and D and the Influence of Major Histocompatibility Complex Polymorphism" J. Exp. Med. (1997) 186(4):549-560	
-		VILLADANGOS, J. A. et al.; "Proteases Involved in MHC Class II Antigen Presentation" Immunological Rev. (1999)172:109- 120	
		VILLADANGOS, J.A. et al.; "Proteolysis in MHC Class II Antigen Presentation: Who's in Charge?"; Immunity (2000) 12:233-239	

Examiner	Date	
Signature	Considered	1

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>1</sup> Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.



JUN 2 8 2002

Approved for use things in the last of the

1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Under the Sawork Reduction A
Substitute for form 1449A/F TRADE

### INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 2

a conceden of information unless it displays a	Taild Offic John of Hamber.
Application Number	10/075,673
Filing Date	February 13, 2002
First Named Inventor	J. Guy Breitenbucher et al.
Group Art Unit	1619
Examiner Name	
Attorney Docket Number	ORT-1590


		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials*	Cite No.1	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
60		ANDRONATI, S.A. et al.: "Synthesis of 1-[4-(4-phenyl-1-piperazinyl)butyl]1,2-dihydro-3H-1,4-benzodiazepin-2-ones and1H-indazoles and their affinity for benzodiazepine receptors"; Chemical Abstracts Number (CAN) 122:314528; (1994) 8:126-131	
		BROMME, D, et al.; "High level expression and crystallization of recombinant human cathepsin S"; Protein Science (1996) 5:789-791	-
		EBERLEIN-KONIG, et al.; "Immunohistochemical investigation of the cellular infiltrates at the sites of allergoid-induced late- phase cutaneous reactions associated with pollen allergen-specific immunotherapy";	
		GAGA, et al; "Eosinophil Activation and T Lymphocyte Infiltration in Allergin-Induced Late Phase Skin Reactions and Classical Delayed-Type Hypersensitivity" J. Immunol. (1991) 147:816-822	
		KIRSCHKE, H. et al.; "Cathepsin S"; Handbook of Proteolytic Enzymes; Barrett, A.J.; Rawlings, N.D.; Woessner, J.F., Editors, Academic Press (1998) 621-624	
		RIESE, R.J. et al.; "Essential Role for Cathepsin S in MHC Class II-Associated Invariant Chain Processing and Peptide Loading"; Immunity (1996) 4:357-366	
		SINGH, P., et al., "Quantitative Structure-Activity Relationship Studies on a New Class of Antihypertensive Agents: Derivatives of 3-Aryl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine"; Quant. StructAct. Relat. (1990) 9:29-32	
Sw		WINTERS, G. et al., "Synthesis in Vitro [3H]Prazosin Displacement and in Vivo Activity of 3-Aryl-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridines, a New Class of Antihypertensive"; J. Med. Chem. (1985) 28(7):934-940	
	_		
	•		

Examiner Signature	6.11	Date Considered	11/10/03	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.



#### **COPY OF PAPERS ORIGINALLY FILED**

PTO/SB/08A (08-00) Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

#### INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet 1 of 2

and not considered. Include copy of this form with next communication to applicant.

a codection of anomiation unless it displays a	TANG ONE CONDUCTION TO
Application Number	10/075,673
Filing Date	F bruary 13, 2002
First Named Inventor	J. Guy Breit nbucher t al.
Group Art Unit	1619
Examiner Name	
Attorney Docket Number	ORT-1590

				U.S. PATENT DOCUMENTS	T	T
Examiner Initials	Cite No.1	U.S. Patent Do	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
	<u> </u>				<del> </del>	
	_				<u> </u>	
			<del>-   -  </del>			
	1		1 1			
			- +			
					<del> </del>	
i		1			•	

FOREIGN PATENT DOCUMENTS Date of Publication Pages, Columns, Lines, Foreign Patent Document of Cited Document where relevant Name of Patentee or passages or relevant ٣ Cite mm-dd-yyyy Examiner Applicant of Cited Document figures appear Initials KindCode<sup>5</sup> Number<sup>4</sup> Office<sup>3</sup> 0 254 241 A1 Yoshitomi Pharmaceutical 01-27-1988 EΡ wo 98/56785 A1 Sumitomo Pharmaceuticals Co. Ltd. 12-17-1998

Examiner Signature	C	[	<u>ф</u>	Date Consider	ed	[1]	110/	03
ACVALUATED.	1-12 dit makes	- annoidered	umo Hor or	not citation is in conformance with MPEP 600	Dra	w line throug	notetion	if noten conformance

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document, s Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST, 16 if possible. • Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

JUL 1 9 2002

**TECH CENTER 1600/2900** 



#### COPY OF PAPERS **ORIGINALLY FILED**

PTO/SB/08A (08-00) Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

#### **INFORMATION DISCLOSURE** STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 2

a conscion or unormation unless it displays a	Valle OMB CULTUUI HUITIDET.
Application Number	10/075,673
Filing Date	F bruary 13, 2002
First Named Inventor	J. Guy Breitenbuch r et al.
Group Art Unit	1619
Examiner Name	
Attorney Docket Number	ORT-1590

		OTHER PRIOR ART, MON PATENT LITERATURE POSITIVENTS	
		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's	Cite No.1	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
SU	,	NAKATSUKA, MASASHI et al. "Preparation of pyrazole derivatives as immunosuppressants" Abstrat retrieved from STN Database accession no. 130:52417, Sumitomo Pharmaceuticals Co., Ltd., Japan 1998	

Examiner Signature	5.00	Date Considered	12/	10/	07	
				,		

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

JUL 1 9 2002

TECH CENTER 1600/2900

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

# JUL 1 6 2002 A

#### COPY OF PAPERS ORIGINALLY FILED

### SUBMISSION UNDER MPEP 609 D

Page 1 of 1

Examiner

Application Number	10/075,673
Filing Date	February 13, 2002
First Named Inventor	J. Guy
	Breitenbucher et al.
Group Art Unit	1619
Examiner Name	
Attorney Docket Number	ORT-1590

Examiner Initials No.1 Name of Patentee or Applicant of Cited Document U.S. Patent Document U.S. Patent Document Kind Code<sup>x</sup> (if known) Pages, Columns, Lines, where relevant passages or relevant figures appear

**FOREIGN PATENT DOCUMENTS** Foreign Patent Document Pages, Columns, Lines, where relevant passages Name of Patentee or or relevant figures Examiner Cite T٥ Applicant of Cited Document Number<sup>4</sup> KindCode<sup>5</sup> appear Office<sup>3</sup> No.1 OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), T² Examiner Cite title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), No.1 volume-issue number(s), publisher, city and/or country where published PCT Search Report - International Application No. PCT/US01/27479 - Ortho McNeil Pharmaceutical, Inc.

RECEIVED

JUL 1 9 2002

TECH CENTER 1600/2900

O PE VOLO SUBSTITUTE O PE VOLO

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 1

a collection of information unless it displays a valid OMB control number.				
Application Number	10/075,673			
Filing Date	February 13, 2002			
First Named Inventor	J. Guy Breitenbucher			
Group Art Unit	1619			
Examiner Name	Unknown			
Attorney Docket Number	ORT-1590			

	U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.1	U.S. Patent Do	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear

**FOREIGN PATENT DOCUMENTS** Foreign Patent Document Date of Publication Pages, Columns, Lines, of Cited Document where relevant Name of Patentee or passages or relevant Examiner Cite mm-dd-yyyy Applicant of Cited Document figures appear Initials Office<sup>3</sup> Number⁴ KindCode<sup>5</sup> No.1 wo 01/40204 Ono Pharmaceutical Co. 06/07/2001 wo 01/19796 Α Axvs Pharmaceuticals, Inc. 03/22/2001 wo 01/09110 Α 02/08/2001 Boehringer Ingelheim Pharmaceuticals, Inc. wo 00/55144 Axys Pharmaceuticals, Inc. 09/21/2000 wo Α 09/08/2000 00/51998 Boehringer Ingelheim Pharmaceuticals, Inc. wo 00/49008 08/24/2000 Α Astrazeneca AB 99/48911 09/30/1999 Synphar Laboratories, Inc.

Examiner Signature	51160	Date Considered	4/10/07	

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washinton, DC 20231.

nmissioner for Patents, Washington, DC 202:

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

O P E VO TO SHEAT & TRADER OF

## SUBMISSION UNDER MPEP 609 D

Page 1 of 1

	Application Number	10/075,673
	Filing Date	February 13, 2002
	First Named Inventor	J. Guy
P 609 D	i	Breitenbucher
	Group Art Unit	1619
	Examiner Name	unknown
	Attorney Docket Number	ORT-1590
U.S. PATENT	OCUMENTS	

	Cite			U.S. Patent Document					
Examiner Initials		Name of Patentee or Applicant of Cited Document		Kind Code <sup>2</sup> Number (if known)				Pages, Columns, Lines, where relevant passages or relevant figures appear	
	I NO.					<del>`</del>	T		
	ľ			-					
-									
-									
		FOREIG	NΡ	ATENT	DOCUME	NTS			
Examiner Initials	Cite	Name of Patentee or Applicant of Cited Document		oreign Pa	itent Docum	Columns, Lines, elevant passages elevant figures appear	T <sup>6</sup>		
	140.	·	1						
								,,	
		OTHER PRIOR ART - N	ION	PATENT	LITERATU	RE DOCUME	NTS		,
Examiner 's Initials*	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriat title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(stopped) volume-issue number(s), publisher, city and/or country where published								T²
10	Ĺ	PCT Search Report for PCT/US 01/27441 dated July18, 2002							
7	ļ								
	<del></del>								
	-								
									L

Examiner Signature 91 Date Considered 11/0/03

THE STATE OF THE S